Current Status And Dilemma Of Second-Line Treatment In Advanced Pancreatic Cancer: Is There A Silver Lining?

Jie Hua,Si Shi,Dingkong Liang,Chen Liang,Qingcai Meng,Bo Zhang,Quanxing Ni,Jin Xu,Xianjun Yu

DOI: https://doi.org/10.2147/OTT.S166405

IF: 4

2018-01-01

OncoTargets and Therapy

Abstract:Pancreatic cancer remains one of the most lethal malignant diseases worldwide. The majority of patients present with advanced disease and, therefore, need palliative chemotherapy. Some chemotherapeutic regimens have been well established as first-line therapies and have been shown to increase survival; however, almost all patients with advanced pancreatic cancer will experience disease progression after first-line therapy. Nevertheless, many patients who retain good performance status after initial treatment remain good candidates for additional therapy. Historically, few studies have assessed second-line therapy, with most reports representing small phase II trials with variable findings; however, clinical research for second-line treatment has increased in the past decade, and several randomized controlled trials using different regimens have been published. The current literature shows varying results on treatment efficacy and tolerability. Thus, we reviewed the published data on the use of chemotherapy in the second-line setting for the treatment of advanced pancreatic cancer.